gInstitute for Global Health and Infectious Diseases, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA hDivision of AIDS, National Institute of Allergy and Infectious Diseases, ...

Additionally, some infections may exacerbate or trigger psoriasis, such as strep throat. Regardless of whether you are on a biologic or immunosuppressive medication for psoriasis, it’s essential ...

Psoriasis can be unpredictable. Even if you are taking all your medications correctly, you can experience unexpected flare-ups. The good news is, dietary changes, supplements, and alternative ...

Risankizumab [Skyrizi] is the first inhibitor of the p19 ... Prior research has demonstrated that empiric dose intensification of ustekinumab [Stelara], an IL12 and IL23 antagonist, successfully ...

Both mild and moderate-to-severe psoriasis are significantly associated with an increased risk for sleep disorders, according to a study published online May 13 in JEADV Clinical Practice.

1495 patients received at least 1 dose of bimekizumab for a total of 4749 patient-years (PY) of exposure. Among those receiving bimekizumab continuously, 76.2% had complete skin clearance at week 52, ...

Alumis Inc. has announced the successful completion of patient enrollment in its pivotal Phase 3 ONWARD clinical program for ESK-001, a treatment for moderate-to-severe plaque psoriasis ...

This study is the first randomized, double-blind, controlled Phase 3 clinical study evaluating biologics switching in psoriasis patients ... maintenance treatment dosing every 12 weeks.

Even when medication clears skin symptoms, people with psoriasis can still have inflammation throughout their bodies that increases the risk of obesity, heart disease, and liver issues.